SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    See WA, McLeod D, Iversen P, Wirth M. The bicalutamide Early Prostate Cancer program: demography. Urol Oncol 2001; 6: 437
  • 2
    See W, Iversen P, McLeod D, Wirth M, Morris T, Carroll K. Bicalutamide 150 mg alone or as adjuvant to standard care significantly improves progression-free survival in patients with early, non-metastatic prostate cancer (median 5.4 years’ follow-up). J Urol 2004; 171 (Suppl): 214, A810
  • 3
    See WA, Wirth MP, McLeod DG et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002; 168: 42935
  • 4
    See WA, Iversen P, McLeod DG et al. Bicalutamide 150 mg in addition to standard care significantly improves prostate-specific antigen progression-free survival in patients with early, non-metastatic prostate cancer: median 5.4 years’ follow-up. J Urol 2004; 171 (Suppl): 2801, A1062
  • 5
    Iversen P, McLeod D, See W et al. Bicalutamide (‘Casodex’) 150 mg in addition to watchful waiting in patients with early non-metastatic prostate cancer: updated analysis at a median 5.4 years’ follow-up. Eur Urol (Suppl) 2004; 3: 47, A180
  • 6
    McLeod D, Iversen P, See W et al. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy significantly improves progression-free survival in early non-metastatic prostate cancer: results from the bicalutamide early prostate cancer programme after a median 5.4 years’ follow-up. Eur Urol (Suppl) 2004; 3: 48, A182
  • 7
    Wirth M, Iversen P, McLeod D et al. On behalf of the ‘Casodex’ Early Prostate Cancer Trialists’ Group. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: analysis at a median follow-up of 5.4 years. Eur Urol (Suppl) 2004; 3: 48, A181
  • 8
    Anderson J. Treatment of prostate cancer – The role of primary hormonal therapy. EAU Update Series 2003; 1: 329
  • 9
    Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 45561